Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer.
Santo G, Di Santo G, Sviridenko A, Bayerschmidt S, Wirth L, Scherbauer F, Lehmann P, von Guggenberg E, Decristoforo C, Heidegger-Pircher I, Bektic J, Virgolini I.
Santo G, et al. Among authors: virgolini i.
Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):354-365. doi: 10.1007/s00259-024-06905-5. Epub 2024 Sep 3.
Eur J Nucl Med Mol Imaging. 2024.
PMID: 39225826
Free PMC article.